[Drug-induced nephropathy].
Shimizu
Hideaki
H
Department of Nephrology, Chubu Rosai Hospital.
Tanaka
Akio
A
Matsuo
Seiichi
S
D000617:Aminoglycosides / Q000009:adverse effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005355:Fibrosis / Q000139:chemically induced; D005682:Gadolinium / Q000009:adverse effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D008657:Metabolic Clearance Rate
D000617:Aminoglycosides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003287:Contrast Media; D005682:Gadolinium; D003404:Creatinine